Comparative Pharmacology
Head-to-head clinical analysis: DEXLANSOPRAZOLE versus EZALLOR SPRINKLE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEXLANSOPRAZOLE versus EZALLOR SPRINKLE.
DEXLANSOPRAZOLE vs EZALLOR SPRINKLE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Proton pump inhibitor that suppresses gastric acid secretion by specific inhibition of the (H+, K+)-ATPase enzyme system at the secretory surface of the gastric parietal cell.
EZALLOR SPRINKLE (rosuvastatin) is a competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis. It increases hepatic LDL receptor expression, enhancing LDL clearance from plasma and reducing VLDL synthesis.
30 mg orally once daily for 4 weeks for healing of erosive esophagitis; maintenance therapy: 30 mg orally once daily for up to 6 months. For GERD: 30 mg orally once daily for 4 weeks.
40 mg orally once daily at bedtime; initial dose may be 20 mg. Dose range: 20-80 mg orally once daily.
None Documented
None Documented
Clinical Note
moderateDexlansoprazole + Clodronic acid
"The therapeutic efficacy of Clodronic acid can be decreased when used in combination with Dexlansoprazole."
Clinical Note
moderateDexlansoprazole + Alendronic acid
"The therapeutic efficacy of Alendronic acid can be decreased when used in combination with Dexlansoprazole."
Clinical Note
moderateDexlansoprazole + Technetium Tc-99m medronate
"The therapeutic efficacy of Technetium Tc-99m medronate can be decreased when used in combination with Dexlansoprazole."
Clinical Note
moderate1-2 hours; clinical context: duration of acid suppression exceeds half-life due to binding to proton pumps
Terminal elimination half-life is approximately 19 hours (range 13-20 hours) in healthy volunteers; half-life is prolonged in patients with hepatic impairment and severe renal impairment, necessitating dose adjustments.
Renal: 0% unchanged; metabolites eliminated via urine (51%) and feces (48%)
Renal excretion accounts for approximately 88% of the administered dose (56% as unchanged rosuvastatin and 32% as metabolites); fecal excretion accounts for approximately 12%.
Category A/B
Category C
Proton Pump Inhibitor
Proton Pump Inhibitor
Dexlansoprazole + Pamidronic acid
"The therapeutic efficacy of Pamidronic acid can be decreased when used in combination with Dexlansoprazole."